Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 14,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 14,000 shares of the stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $24.72, for a total value of $346,080.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.25, for a total value of $59,312.50.
• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $55,152.50.
• On Monday, January 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.81, for a total value of $51,382.50.

Enliven Therapeutics Stock Performance

ELVN opened at $19.94 on Tuesday. The firm has a market cap of $821.53 million, a P/E ratio of -9.10 and a beta of 1.06. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $26.00. The business’s fifty day moving average is $16.88 and its 200-day moving average is $14.25.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.09. On average, research analysts predict that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Mizuho started coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price on the stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ELVN. Barclays PLC bought a new position in Enliven Therapeutics in the first quarter valued at about $158,000. Bank of New York Mellon Corp bought a new position in Enliven Therapeutics in the first quarter valued at about $335,000. Tower Research Capital LLC TRC bought a new position in Enliven Therapeutics in the first quarter valued at about $36,000. Citigroup Inc. bought a new position in Enliven Therapeutics in the first quarter valued at about $247,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Enliven Therapeutics during the first quarter worth about $217,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.